Montrouge, France, September 2 (10:30 p.m. CEST), 2022
DBV Technologies
invite
e
at
to present
during the next conferences
ences investors
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, CEO of DBV Technologies, will attend the next investor conferences in September.
Wells Fargo Healthcare Conference
September 7-9, 2022 | Face-to-face conference | Boston, MA
Daniel Tassé will be in Boston on Thursday, September 8, 2022 to participate in a fireside chat at 4:20 p.m. ET (10:20 p.m. CEST).
HC Wainwright
2
4
rd
Annual Global Investment Conference
From September 12 to 14, 2022 | Hybrid face-to-face and virtual conference | New York, NY
Daniel Tassé will be in New York on Monday, September 12, 2022 for a company presentation at 11:00 a.m. ET (5:00 p.m. CEST).
A webcast of the fireside chat and company presentation will be available in the Investors and Media section of the company’s website: https://www.dbv-technologies.com/investor-relations/. A replay of both engagements will also be available on the DBV Technologies website following the conclusion of the events.
HAS
in relation to
DBV Technologies
DBV Technologies is developing Viaskin™, an experimental proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on Epicutaneous Immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company aims to safely transform the treatment of patients with food allergies. DBV Technologies’ food allergy programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies’ global headquarters are located in Montrouge, France, and its North American operations are based in Basking Ridge, NJ. The Company’s ordinary shares are traded on the B segment of Euronext Paris (symbol: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing half an ordinary share) are traded on the Nasdaq Global Select Market ( symbol: DBVT).
Contact Investors
Anne Pollack
DBV Technologies
+1 857-529-2363
[email protected]
Contact
Media
Angela Marcucci
DBV Technologies
+1 646-842-2393
Attachment